The COVID-19 pandemic
rapidly became a worldwide healthcare emergency
affecting millions of people, with poor outcomes for patients with
chronic conditions and enormous pressure on healthcare systems. Pulmonary
fibrosis (PF) has been cited as a risk factor for a more severe evolution
of COVID-19, primarily because its acute exacerbations are already
associated with high mortality. We reviewed the available literature
on biochemical, pathophysiological, and pharmacological mechanisms
of PF and COVID-19 in an attempt to foresee the particular risk of
infection and possible evolution of PF patients if infected with SARS-COV-2.
We also analyzed the possible role of medication and risk factors
(such as smoking) in the disease’s evolution and clinical course.
We found out that there is a complexity of interactions between coexisting
idiopathic pulmonary fibrosis/interstitial lung disease (ILD) and
COVID-19 disease. Also, patients recovering from severe COVID-19 disease
are at serious risk of developing PF. Smokers seem to have, in theory,
a chance for a better outcome if they develop a severe form of COVID-19
but statistically are at much higher risk of dying if they become
critically ill.